The possible role of lycopene on the cerebellum of albino rat prenatally exposed to valproic acid: Animal model of autism spectrum disorder.

Researchers studied whether lycopene (a natural antioxidant found in tomatoes) could protect against brain damage caused by valproic acid, a seizure medication that increases autism risk when taken during pregnancy. In pregnant rats, lycopene prevented the brain damage and inflammation that valproic acid typically causes. This suggests lycopene might help protect developing brains, though more research in humans is needed.

This preclinical study investigated lycopene's protective effects against valproic acid (VPA)-induced cerebellar damage in a rat model of autism spectrum disorder. Pregnant rats received VPA (50mg/kg/day), known to cause autism-like symptoms in offspring, with or without lycopene supplementation (5mg/kg/day). VPA exposure caused cerebellar degeneration, increased inflammatory markers (GFAP, TNF-α), oxidative stress (MDA), and altered neurotransmitter systems while reducing protective factors (BDNF, SOD). Lycopene treatment reversed these pathological changes through antioxidant and anti-inflammatory mechanisms.

The study demonstrates lycopene's potential neuroprotective properties in preventing VPA-induced cerebellar damage, suggesting possible therapeutic applications for autism spectrum disorder.

While promising for neuroprotection, this animal research cannot guide clinical practice. Human studies needed before considering lycopene supplementation for autism prevention. Results support further investigation of antioxidant interventions in autism spectrum disorder development.

This is an animal study using rats, limiting direct translation to humans. Sample size details not provided. Single-dose lycopene tested. No behavioral autism assessments reported. Long-term effects unknown. Mechanism understanding remains incomplete.

Autism is a serious neurodevelopmental disorder with a rising global prevalence. Prenatal exposure to valproic acid (VPA), a common antiepileptic drug, is associated with autism in offspring. Lycopene, a potent antioxidant and anti-inflammatory compound, may counteract VPA-induced neurotoxicity. To the best of our knowledge, this research is the first attempt to assess the beneficial role of lycopene supplementation in a VPA model of autism.

In total, 30 pregnant female albino rats were grouped into five groups: control, lycopene-treated (5 mg/kg/day orally), VPA-treated (50 mg/kg/day orally), VPA-protected with lycopene, and VPA-treated with lycopene. After the scarification of rats, biochemical, histological, immunohistochemical, and ultrastructural analyses were performed on the cerebellum. VPA produced degenerative changes in the cerebellum with increased glial fibrillary acidic protein (GFAP) and Bax while decreasing myelin basic protein (MBP) and Tau1 expressions. Moreover, it increased the brain levels of malondialdehyde (MDA), acetylcholinesterase enzyme (AChE), tumor necrosis factor-alpha (TNF-α), and glutamate.

It also reduced brain-derived neurotrophic factor (BDNF) and superoxide dismutase (SOD) levels. Lycopene reversed these effects by reducing oxidative stress and inflammatory markers, and restoring antioxidant levels. In conclusion, lycopene mitigated VPA-induced cerebellar damage through its antioxidant and anti-inflammatory effects and its ability to modulate neurotransmission, suggesting a potential therapeutic role in autism.